Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Partnering Agreements with Gilead 2010 (CurrentPartnering)
- Market: Healthcare and Medical
- Published Date: 28 Jan 2010
- Report Title: Partnering Agreements with Gilead 2010
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 55
The Partnering Agreements with Gilead 2010 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
This report provides all the information you require to better understand Gilead Labs and its partnering interests and activities over the past five years.
Using this report, dealmakers will effectively and efficiently determine the suitablility of Gilead as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.
The report provides a firm basis for initial due diligence into Gilead as a prospective partner company.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005 to 2009 according to reported deal size.
Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.
Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area.
The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.
The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently.
Key benefits
Partnering Agreements with Gilead 2010 report provides the user with the following key benefits:
Detailed company profile of the company
In-depth marketed and pipeline product activity for the company
Partnering interests and therapy focus revealed
Partnering activity since 2000 – number of deals per year
Partnering activity for 2005-2009
Activity by deal type
Activity by phase of development
Activity by therapeutic area
List of recent partner companies
Comprehensive access to actual contracts entered into by the company and its partners
Insight into the terms included in a partnering agreement
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Partnering Agreements with Gilead 2010 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
Partnering Agreements with Gilead 2010 includes:
Detailed company profile including:
Full contact details
Business developer contact details including name, title, email and telephone (where available)
Marketed indications
Pipeline indications
Partnering interests and indications
Partnering activity since 2000
Current partner companies since 2005
Partnering activity since 2005 by:
Deal type
Stage of development
Therapy area
Numerous charts showing the dealmaking activity of the company since 2005
The tools to enable effective and efficient preparation for partnering negotiation with the company
Listing of contract documents between the company and its partners
The leading M&A and partnering deals by value 2005-2009
Most active M&A and partnering dealmakers 2005-2009
This report provides all the information you require to better understand Gilead Labs and its partnering interests and activities over the past five years.
Using this report, dealmakers will effectively and efficiently determine the suitablility of Gilead as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.
The report provides a firm basis for initial due diligence into Gilead as a prospective partner company.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005 to 2009 according to reported deal size.
Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.
Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area.
The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.
The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently.
Key benefits
Partnering Agreements with Gilead 2010 report provides the user with the following key benefits:
Detailed company profile of the company
In-depth marketed and pipeline product activity for the company
Partnering interests and therapy focus revealed
Partnering activity since 2000 – number of deals per year
Partnering activity for 2005-2009
Activity by deal type
Activity by phase of development
Activity by therapeutic area
List of recent partner companies
Comprehensive access to actual contracts entered into by the company and its partners
Insight into the terms included in a partnering agreement
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Partnering Agreements with Gilead 2010 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
Partnering Agreements with Gilead 2010 includes:
Detailed company profile including:
Full contact details
Business developer contact details including name, title, email and telephone (where available)
Marketed indications
Pipeline indications
Partnering interests and indications
Partnering activity since 2000
Current partner companies since 2005
Partnering activity since 2005 by:
Deal type
Stage of development
Therapy area
Numerous charts showing the dealmaking activity of the company since 2005
The tools to enable effective and efficient preparation for partnering negotiation with the company
Listing of contract documents between the company and its partners
The leading M&A and partnering deals by value 2005-2009
Most active M&A and partnering dealmakers 2005-2009
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
